Agilent companion diagnostic expands ce-ivd mark for pd-l1 ihc 28-8 pharmdx to include muscle-invasive urothelial carcinoma (miuc)

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced ce-ivd marking in the european union for its pd-l1 ihc 28-8 pharmdx immunohistochemical assay to extend the use of the test to patients diagnosed with muscle-invasive urothelial carcinoma (miuc) who have tumor cell pd-l1 expression ≥ 1% for adjuvant treatment with opdivo® (nivolumab), a pd-1-targeted immunotherapeutic from bristol myers squibb. urothelial carcinoma is the 10th most common cancer worldwide,
A Ratings Summary
A Quant Ranking